通过肠道载体介导的塔利诺洛尔的区域吸收:PBPK建模分析的见解
Kazuya Ishida1, Xiaomin Liang1, Fulden Buyukozturk2
1Drug Metabolism, Gilead Sciences, Inc., Foster City, CA, United States.
Frontiers in pharmacology
|February 27, 2026
概括
肠道载体的区域差异解释了双重药物吸收峰值. 建模表明,特定肠道区域的输送器活性是理解复杂药物度-时间概况的关键.
科学领域:
- 药理动力学和药物新陈代谢
- 胃肠道生理学 胃肠道生理学
- 计算生物学 计算生物学
背景情况:
- 肠道载体显著影响口服药物吸收,影响药物动力学变异性和药物相互作用.
- 在药物血度-时间概况中观察到的双重或多重吸收峰值表明了复杂的潜在机制.
- 在这些现象中,区域性肠道输送体表达和相互作用的作用仍然在很大程度上未被探索.
研究的目的:
- 为了研究像塔利诺洛尔这样的药物的双重吸收峰值背后的机制.
- 为了检查塔利诺洛尔的度和pH值依赖的运输,P-glycoprotein (P-gp) 的基质和有机离子运输聚 (OATP) 2B1.1.
- 开发和完善一个以生理学为基础的药理动力学 (PBPK) 模型,包括区域转运体活动.
主要方法:
- 利用Caco-2细胞测试来评估塔利诺洛尔的运输特性,包括pH依赖性.
- 在先进的溶解,吸收和新陈代谢 (M-ADAM) 框架内开发了一种多层肠壁PBPK模型.
- 通过调整区域传送器表达和活动以匹配实验数据,代地改进了PBPK模型.
主要成果:
- 发现P-gp的塔利诺洛运输依赖于pH值,在较低的pH值下降了底侧到顶峰的透性.
- 结合Caco-2数据和P-gp表达的初始PBPK模型无法复制文献中报告的塔利诺洛血度概况.
- 调整区域输送活动,特别是调节顶吸收和顶和顶的基侧流量,对于模拟双重吸收峰值至关重要.
结论:
- 肠道吸收和排放载体活性的区域差异是复杂药物吸收特征的关键决定因素,例如对talinolol观察到的双峰.
- 这项研究强调了需要考虑肠道内的传送器功能的空间异质性的必要性.
- 需要进行进一步的研究,以探索额外的载体在肠细胞内的底侧运输中的作用.
相关概念视频
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
354
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
354
Physiological Pharmacokinetic Models: Blood Flow-Limited Versus Diffusion-Limited Models
397
Physiological pharmacokinetic models, often called flow-limited or perfusion models, typically assume a swift drug distribution between tissue and venous blood, creating a rapid drug equilibrium. This premise is based on the idea that drug diffusion is extremely fast, and the cell membrane presents no barrier to drug permeation. In this scenario, where no drug binding occurs, the drug concentration in the tissue equals that of the venous blood leaving the tissue. This greatly simplifies the...
397
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
77
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
77
One-Compartment Open Model for Extravascular Administration: First-Order Absorption Model
638
The first-order absorption model for extravascular administration describes the rate at which a drug is absorbed and eliminated, following the principles of first-order kinetics. This model is vital as it provides a mathematical representation of drug behavior within the body. It also allows for the prediction and interpretation of drug absorption and elimination based on the rate of change in drug concentration over time. This model can be visualized as a plasma concentration-time profile...
638
One-Compartment Open Model: Wagner-Nelson and Loo Riegelman Method for ka Estimation
1.3K
This lesson introduces two critical methods in pharmacokinetics, the Wagner-Nelson and Loo-Riegelman methods, used for estimating the absorption rate constant (ka) for drugs administered via non-intravenous routes. The Wagner-Nelson method relates ka to the plasma concentration derived from the slope of a semilog percent unabsorbed time plot. However, it is limited to drugs with one-compartment kinetics and can be impacted by factors like gastrointestinal motility or enzymatic degradation.
On...
On...
1.3K
One-Compartment Open Model for IV Bolus Administration: General Considerations
843
The one-compartment model is a pharmacokinetic tool that models the body as a single, uniform compartment, facilitating the understanding of drug distribution and elimination. This model is particularly beneficial for intravenous (IV) bolus administration, where the drug rapidly circulates throughout the body.
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
843


